Literature DB >> 33715037

Pleural effusion-based nomogram to predict outcomes in unselected patients with multiple myeloma: a large single center experience.

Zi-Liang Hou1,2, Yu Kang3, Guang-Zhong Yang4, Zhen Wang1, Feng Wang1, Yan-Xia Yu1, Wen-Ming Chen5, Huan-Zhong Shi6.   

Abstract

Pleural effusion (PE) is prevalent in unselected "real-life" populations of multiple myeloma (MM). However, its prognostic value on MM is currently elusive. This study aimed to explore the role of PE on MM prognosis and to develop a novel prognostic nomogram for a cohort of Chinese patients with MM. Patients diagnosed with MM form 2000 through 2017 were retrospectively enrolled. PE was evaluated by chest computed tomography (CT) scans. Independent predictors of overall survival (OS) were identified using a multivariable Cox regression model performed on variables selected by the least absolute shrinkage and selection operator (LASSO) algorithm. A nomogram was constructed based on these variables. The concordance index (C-index) and the calibration curve were used to evaluate the predictive performance of the nomogram. Among 861 patients analyzed, 368 patients developed PE. Multivariate cox regression and restricted mean survival time (RMST) analyses revealed that patients with PE experienced worse OS vs. patients without PE. A nomogram predictive of OS was constructed using PE, plasma cell proportion, international staging system (ISS) stage, Charlson comorbidity index (CCI), 1q21 gain, and autologous hematopoietic stem cell transplantation (HSCT). The nomogram showed satisfactory discrimination in the derivation cohort (C-index=0.729) and the validation cohort (C-index=0.684), outperforming the Durie-Salmon (DS) and ISS staging systems. Moreover, the nomogram accurately classified patients into two distinct high- and low-risk groups. PE is frequently encountered in the disease course for MM patients. We derivated and validated a novel nomogram for MM based on PE, outperforming the DS/ISS staging systems.

Entities:  

Keywords:  Multiple myeloma; Nomogram; Pleural effusion; Prognosis; Risk score

Year:  2021        PMID: 33715037     DOI: 10.1007/s00277-021-04484-1

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  45 in total

1.  Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.

Authors:  Yoshihiro Inamoto; Shingo Kurahashi; Nobuhiko Imahashi; Nobuaki Fukushima; Tatsuya Adachi; Tomohiro Kinoshita; Keitaro Tsushita; Koichi Miyamura; Tomoki Naoe; Isamu Sugiura
Journal:  Am J Hematol       Date:  2009-05       Impact factor: 10.047

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents.

Authors:  Evangelos Terpos; Eirini Katodritou; Maria Roussou; Anastasia Pouli; Eurydiki Michalis; Sosana Delimpasi; Agapi Parcharidou; Zafiris Kartasis; Athanasios Zomas; Argiris Symeonidis; Nora-Athina Viniou; Nikolaos Anagnostopoulos; Theofanis Economopoulos; Konstantinos Zervas; Meletios A Dimopoulos
Journal:  Eur J Haematol       Date:  2010-05-06       Impact factor: 2.997

4.  Proceedings: Detection of carriers of haemophilia using linear discriminant analysis.

Authors:  C R Prentice; C D Forbes; S Smith; D McLaren
Journal:  Br J Haematol       Date:  1974-06       Impact factor: 6.998

5.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

6.  Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma.

Authors:  Maria Gkotzamanidou; Efstathios Kastritis; Maria Roussou Magdalini Migkou Maria Gavriatopoulou; Nikitas Nikitas; Dimitra Gika; Despina Mparmparousi; Charis Matsouka; Evangelos Terpos; Meletios A Dimopoulos
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-09-08

7.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

8.  Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-related death.

Authors:  Philippe Moreau; Michele Cavo; Pieter Sonneveld; Laura Rosinol; Michel Attal; Annalisa Pezzi; Hartmut Goldschmidt; Juan Jose Lahuerta; Gerald Marit; Antonio Palumbo; Bronno van der Holt; Joan Bladé; Maria Teresa Petrucci; Kai Neben; Jesus san Miguel; Francesca Patriarca; Henk Lokhorst; Elena Zamagni; Cyrille Hulin; Norma Gutierrez; Thierry Facon; Denis Caillot; Lotfi Benboubker; Jean-Luc Harousseau; Xavier Leleu; Hervé Avet-Loiseau; Jean-Yves Mary
Journal:  J Clin Oncol       Date:  2014-06-02       Impact factor: 44.544

9.  A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial.

Authors:  K D Boyd; F M Ross; L Chiecchio; G P Dagrada; Z J Konn; W J Tapper; B A Walker; C P Wardell; W M Gregory; A J Szubert; S E Bell; J A Child; G H Jackson; F E Davies; G J Morgan
Journal:  Leukemia       Date:  2011-08-12       Impact factor: 11.528

10.  Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma.

Authors:  Efstathios Kastritis; Evangelos Terpos; Maria Roussou; Maria Gavriatopoulou; Magdalini Migkou; Evangelos Eleutherakis-Papaiakovou; Despoina Fotiou; Dimitrios Ziogas; Ioannis Panagiotidis; Eftychia Kafantari; Stavroula Giannouli; Athanasios Zomas; Konstantinos Konstantopoulos; Meletios A Dimopoulos
Journal:  Haematologica       Date:  2016-10-27       Impact factor: 9.941

View more
  2 in total

1.  Development and Validation of a Novel Prognostic Model for Overall Survival in Newly Diagnosed Multiple Myeloma Integrating Tumor Burden and Comorbidities.

Authors:  Shuangshuang Jia; Lei Bi; Yuping Chu; Xiao Liu; Juan Feng; Li Xu; Tao Zhang; Hongtao Gu; Lan Yang; Qingxian Bai; Rong Liang; Biao Tian; Yaya Gao; Hailong Tang; Guangxun Gao
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

2.  Predicting the risk of acute kidney injury after hematopoietic stem cell transplantation: development of a new predictive nomogram.

Authors:  Zhaoping Gan; Liyi Chen; Meiqing Wu; Lianjin Liu; Lingling Shi; Qiaochuan Li; Zhongming Zhang; Yongrong Lai
Journal:  Sci Rep       Date:  2022-09-12       Impact factor: 4.996

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.